Open AccessPROTECTIVE EFFECT OF CTLA4Ig SECRETED BY TRANSGENIC FETAL PANCREAS ALLOGRAFTS1
Author(s) -
Robyn M. Sutherland,
Jamie L. Brady,
Harry M. Georgiou,
Helen E. Thomas,
Andrew M. Lew
Publication year - 2000
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/00007890-200005150-00013
Subject(s) - immunosuppression , allotransplantation , transgene , islet , transplantation , pancreas , biology , immunology , immune system , pancreatic islets , genetically modified mouse , immune tolerance , insulin , endocrinology , medicine , biochemistry , gene
Pancreas allotransplantation offers a cure for insulin-dependent diabetes mellitus. Systemic immunosuppression used to prevent immune destruction of the graft has side-effects, including increased susceptibility to infection and neoplasia. These unwanted effects may be limited by engineering the graft to secrete immunomodulatory molecules, to achieve local immunosuppression. Several studies have shown that transient local CTLA4Ig results in partial protection of allogeneic grafts. Our intent has been to determine whether sustained secretion of transgenic CTLA4Ig from pancreatic islets is able to protect against allograft rejection.